TANDEM DIABETES CARE INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.0B | $940.2M | $747.7M | $801.2M | $702.8M |
| Cost of revenue | $468.7M | $450.6M | $380.0M | $388.2M | $326.6M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M | $376.2M |
| Selling, general & administrative | $445.0M | $389.8M | $352.5M | $335.7M | $261.5M |
| Research and development | $193.1M | $198.9M | $169.7M | $139.1M | $92.1M |
| Operating expenses | $733.3M | $588.7M | $600.9M | $505.8M | $353.6M |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M | $22.7M |
| Interest expense | $7.9M | $7.4M | $9.9M | $6.2M | — |
| Pretax income | -$200.3M | -$91.9M | -$220.3M | -$92.9M | $15.9M |
| Income tax expense | $4.4M | $4.2M | $2.4M | $1.7M | $335,000 |
| Net income | -$204.7M | -$96.0M | -$222.6M | -$94.6M | $15.6M |
| Balance Sheet | |||||
| Cash and equivalents | $90.6M | $69.2M | $58.9M | $172.5M | $71.2M |
| Current assets | $618.1M | $724.5M | $748.0M | $850.0M | $811.5M |
| Total assets | $881.1M | $967.7M | $952.7M | $1.1B | $905.1M |
| Current liabilities | $242.7M | $247.0M | $195.3M | $165.3M | $131.9M |
| Total liabilities | $725.9M | $704.6M | $639.0M | $612.8M | $472.0M |
| Stockholders' equity | $155.2M | $263.1M | $313.6M | $439.9M | $433.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.7M | $24.2M | -$31.8M | $50.5M | $111.4M |
| Depreciation and amortization | $17.7M | $16.6M | $15.7M | $14.3M | $13.8M |
| Stock-based compensation | $92.4M | $101.4M | $88.1M | $84.9M | $60.8M |
| Capital expenditure | $19.9M | $19.2M | $26.8M | $34.1M | $14.2M |
| Free cash flow | -$29.7M | $5.0M | -$58.6M | $16.4M | $97.2M |
| Share repurchases | $0 | $30.0M | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 68.5M · Free float 93.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.